Omeros Past Earnings Performance
Past criteria checks 0/6
Omeros's earnings have been declining at an average annual rate of -11.7%, while the Pharmaceuticals industry saw earnings growing at 1% annually. Revenues have been declining at an average rate of 53% per year.
Key information
-11.7%
Earnings growth rate
-6.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | -53.0% |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Omeros: Still Worth A Look Despite Narsoplimab Woes
Feb 14Is Omeros (NASDAQ:OMER) A Risky Investment?
Jul 26
Omeros (NASDAQ:OMER) Is Making Moderate Use Of Debt
Mar 17Omeros: Taking It To The Max
Oct 05Omeros falls 11% after reporting clinical data for COVID-19 therapy
Sep 15Omeros: Managing An Investment After A Winning Trade
Aug 16Omeros granted FDA’s Orphan Drug designation for PNH candidate
Jul 28Omeros: Follow The Bouncing Ball
Jul 04Omeros: On Death's Door
Jun 02Omeros: The Weight Of The Wait, A Conundrum
May 03Omeros: Despite Its Promise, The CRL Is A Huge Obstacle
Feb 21Omeros: A New Year Beckons
Dec 06Some Analysts Just Cut Their Omeros Corporation (NASDAQ:OMER) Estimates
Dec 04Omeros: What's Left
Oct 15Omeros: The Prize Is Nigh (Again)
Sep 14Omeros: PDUFA Delay Presents An Opportunity
Jul 03Omeros posts preliminary results from early-stage OMS906 trial
Jun 09Should Shareholders Reconsider Omeros Corporation's (NASDAQ:OMER) CEO Compensation Package?
Jun 05Omeros posts preliminary results from COVID-19 patients treated with narsoplimab
May 28CDC and CMS OKs Omeros' ICD-10 codes for HSCT-TMA diagnosis and narsoplimab
May 04What Kind Of Shareholders Own Omeros Corporation (NASDAQ:OMER)?
Mar 03Update: Omeros (NASDAQ:OMER) Stock Gained 73% In The Last Five Years
Jan 27Omeros: A Ripening Fruit Ready To Pick
Dec 09Omeros: Ending 2020 On Some High Notes
Dec 05Rainbows and Unicorns: Omeros Corporation (NASDAQ:OMER) Analysts Just Became A Lot More Optimistic
Dec 05
Revenue & Expenses BreakdownBeta
How Omeros makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -175 | 50 | 45 |
| 30 Sep 23 | 0 | -182 | 52 | 45 |
| 30 Jun 23 | 0 | -185 | 48 | 46 |
| 31 Mar 23 | 0 | -182 | 51 | 46 |
| 31 Dec 22 | 0 | -182 | 51 | 46 |
| 30 Sep 22 | 0 | -183 | 50 | 97 |
| 30 Jun 22 | 0 | -173 | 51 | 45 |
| 31 Mar 22 | 0 | -181 | 53 | 47 |
| 31 Dec 21 | 0 | -192 | 55 | 47 |
| 30 Sep 21 | -63 | -217 | 37 | 111 |
| 30 Jun 21 | -37 | -211 | 43 | 111 |
| 31 Mar 21 | -24 | -194 | 44 | 108 |
| 31 Dec 20 | 0 | -173 | 49 | 43 |
| 30 Sep 20 | 97 | -130 | 71 | 43 |
| 30 Jun 20 | 100 | -108 | 68 | 40 |
| 31 Mar 20 | 114 | -89 | 68 | 40 |
| 31 Dec 19 | 0 | -147 | 40 | 106 |
| 30 Sep 19 | 100 | -79 | 63 | 37 |
| 30 Jun 19 | 75 | -102 | 60 | 36 |
| 31 Mar 19 | 50 | -121 | 55 | 32 |
| 31 Dec 18 | 30 | -127 | 52 | 31 |
| 30 Sep 18 | 22 | -120 | 49 | 29 |
| 30 Jun 18 | 39 | -88 | 47 | 28 |
| 31 Mar 18 | 54 | -68 | 51 | 28 |
| 31 Dec 17 | 65 | -53 | 52 | 27 |
| 30 Sep 17 | 64 | -57 | 52 | 28 |
| 30 Jun 17 | 54 | -63 | 51 | 28 |
| 31 Mar 17 | 46 | -61 | 45 | 27 |
| 31 Dec 16 | 42 | -67 | 44 | 27 |
| 30 Sep 16 | 35 | -67 | 41 | 26 |
| 30 Jun 16 | 27 | -73 | 40 | 27 |
| 31 Mar 16 | 21 | -77 | 37 | 26 |
| 31 Dec 15 | 14 | -75 | 35 | 25 |
| 30 Sep 15 | 7 | -76 | 34 | 25 |
| 30 Jun 15 | 4 | -74 | 31 | 33 |
| 31 Mar 15 | 1 | -76 | 28 | 27 |
| 31 Dec 14 | 1 | -74 | 23 | 21 |
| 30 Sep 14 | 1 | -55 | 17 | 20 |
| 30 Jun 14 | 1 | -50 | 16 | 10 |
| 31 Mar 14 | 1 | -46 | 15 | 14 |
| 31 Dec 13 | 2 | -40 | 15 | 18 |
| 30 Sep 13 | 3 | -46 | 16 | 17 |
| 30 Jun 13 | 4 | -45 | 14 | 16 |
Quality Earnings: OMER is currently unprofitable.
Growing Profit Margin: OMER is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: OMER is unprofitable, and losses have increased over the past 5 years at a rate of 11.7% per year.
Accelerating Growth: Unable to compare OMER's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: OMER is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-13.2%).
Return on Equity
High ROE: OMER's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.